nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Browsing articles in "Bipolar Disorders"

 

Adjunctive Psychotherapy for Bipolar Disorder
October 25, 2020   

Adjunctive psychotherapy is recommended for patients with bipolar disorder; however, the comparative effectiveness of manualized psychotherapies has not been established. Using network meta-analysis...
 Continue reading (Members only)
FDA Committees Vote in Favor of a Combination of Olanzapine and Samidorphan
October 14, 2020   

Two advisory committees, the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the US Food and Drug Administration have voted in favor of ALKS 3831, a combination of olanzapine and samidorphan. The...
 Continue reading
Olanzapine/Samidorphan Combo Found to Reduce Antipsychotic-Induced Weight Gain
September 1, 2020   

The combination of olanzapine, a dopamine D2 receptor antagonist, and samidorphan, an opioid receptor antagonist, is being developed for the treatment of schizophrenia and bipolar I disorder. Despite its efficacy, olanzapine is associated with significant weight gain and adverse metabolic effects that limit its clinical utility as a monotherapy. The combination of olanzapine and samidorphan has been shown to...
 Continue reading (Members only)
NEI Virtual Poster Library is Live!
July 13, 2020   

NEI has launched a Virtual Poster Library to fulfill the needs of poster presenters who had hoped to share their research and findings at medical conferences that have been cancelled due to the COVID-19 pandemic....
 Continue reading
Consensus Statement on Use of Antipsychotic Blood Levels
June 23, 2020   

It has been known that the quantification of antipsychotic levels in blood, known as therapeutic monitoring can be helpful in determining appropriate therapeutic dosing, and augmentation for treatment. It can be a useful tool for antipsychotics to manage challenging clinical scenarios, such as lack of therapeutic response, relapse, or adverse drug reactions (ADRs) related to antipsychotic treatment, especially...
 Continue reading (Members only)
FDA Grants Breakthrough Device Designation to TMS Device for Bipolar Depression
March 26, 2020   

The U.S. Food and Drug Administration has granted Breakthrough Device designation for NeuroStar® Advanced Therapy, a transmagnetic stimulation (TMS) device, for the treatment of bipolar depression. Although TMS is approved for the treatment of...
 Continue reading (Members only)
Severe Clinical Consequences of Childhood Abuse and Neglect
February 10, 2020   

l infarction, cerebrovascular disease, type 2 diabetes, asthma, cancer, and overall lowered life expectancy. In this article, the authors review the current state of research regarding the association of early childhood abuse/neglect with development of psychiatric illness, particularly mood disorders such as...
 Continue reading (Members only)
Predicting Bipolar Disorder
October 11, 2019   

The International Society of Bipolar Disorders (ISBD) task force has recently published work attempting to identify some of the precursors and prodromes that may predict eventual diagnosis of bipolar disorder...
 Continue reading
Cariprazine Now Approved for Full Spectrum of Bipolar I Disorder Symptoms
June 7, 2019   

The U.S. Food and Drug Administration has approved the supplemental new drug application for cariprazine for the treatment of depressive episodes associated with bipolar I disorder in adults. In the three studies submitted with the supplemental new drug application, including...
 Continue reading
Age and Mixed Features May Predict Next-Step Strategies for Depression Remission
May 25, 2019   

Approximately 2/3 of patients with major depressive disorder (MDD) do not achieve remission despite adequate treatment with an antidepressant. It would be of utmost benefit to clinicians to be able to predict which patients would do better with which specific next-step treatment strategies -whether it be switching to a different antidepressant, combination of two antidepressants, or augmentation with a psychotropic from another drug class -rather than relying on trial and error...
 Continue reading
1234
Top of Page